The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone SarcomasNicoletta Polerà, Pierfrancesco Tassone|Cancers|2023Cited by 3